| ASSET | YEAR | % RETURN |
|---|---|---|
Avalo Therapeutics (AVTX) | 2023 | -99.25% |
Gorilla Technology (GRRR) | 2023 | -95.4% |
Aclaris Therapeutics (ACRS) | 2023 | -93.41% |
ESGL (OIO) | 2023 | -93.16% |
Better Home & Finance (BETR) | 2023 | -91.9% |
Nutex Health (NUTX) | 2023 | -90.63% |
Strive Asset Management (ASST) | 2023 | -89.13% |
Tenax Therapeutics (TENX) | 2023 | -87.84% |
Palisade Bio (PALI) | 2023 | -87.34% |
Arqit Quantum (ARQQ) | 2023 | -86.87% |
Monopar Therapeutics (MNPR) | 2023 | -86.29% |
AMC Entertainment (AMC) | 2023 | -85.22% |
SEALSQ (LAES) | 2023 | -84.94% |
Palvella Therapeutics (PVLA) | 2023 | -81.8% |
Emergent Biosolutions (EBS) | 2023 | -80.1% |
Prenetics Global (PRE) | 2023 | -80% |
Enanta Pharmaceuticals (ENTA) | 2023 | -79.86% |
Novocure (NVCR) | 2023 | -79.86% |
Canopy Growth (CGC) | 2023 | -78.44% |
Uxin (UXIN) | 2023 | -76.08% |
ProKidney (PROK) | 2023 | -75.68% |
Blue Ridge Bankshares (BRBS) | 2023 | -75.01% |
Design Therapeutics (DSGN) | 2023 | -74.37% |
Replimune (REPL) | 2023 | -69.46% |
Compass Therapeutics (CMPX) | 2023 | -69.35% |
Small-cap stocks are treated as having a market cap between $300M and $2B.